Calidad de vida en pacientes intervenidas de cáncer de mama

El tractament quirúrgic pot unfluir en la qualitat de vida relacionada amb la salut (QVRS) de les dones amb cáncer de mama. Es descriuen les característiques de les paciente, l ´evolució de la seua QVRS i les diferències segons la intervenció quirúrgiaca. La QVRD s´ha mesurat mitjançant el EuroQol-5D, EORTC QLQ-C30 i EORTC QLQ-BR23. Es van incloure 205 pacients. Respecte al EuroQol, l´Escala Visual Analògica va millorar (P&0.0001), però, la tarifa no va mostrar canvis significatius (P=0.1323). En canvi, EORTC QLQ-C30 va millorar (p&0.0001). Hi ha beneficis del a cirurgia conservadora en QVRS, la qual va ser bona y va millorar amb el seguiment.

A consistency test of the time trade-off

This paper tests the internal consistency of time trade-off utilities.We find significant violations of consistency in the direction predictedby loss aversion. The violations disappear for higher gauge durations.We show that loss aversion can also explain that for short gaugedurations time trade-off utilities exceed standard gamble utilities. Ourresults suggest that time trade-off measurements that use relativelyshort gauge durations, like the widely used EuroQol algorithm(Dolan 1997), are affected by loss aversion and lead to utilities thatare too high.

Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol.

Background: Treatment of depression, the most prevalent and costly mental disorder, needs to be improved. Non-concordance with clinical guidelines and non-adherence can limit the efficacy of pharmacological treatment of depression. Through pharmaceutical care, pharmacists can improve patients' compliance and wellbeing. The aim of this study is to evaluate the effectiveness and costeffectiveness of a community pharmacist intervention developed to improve adherence and outcomes of primary care patients with depression. Methods/design: A randomized controlled trial, with 6-month follow-up, comparing patients receiving a pharmaceutical care support programme in primary care with patients receiving usual care. The total sample comprises 194 patients (aged between 18 and 75) diagnosed with depressive disorder in a primary care health centre in the province of Barcelona (Spain). Subjects will be asked for written informed consent in order to participate in the study. Diagnosis will be confirmed using the SCID-I. The intervention consists of an educational programme focused on improving knowledge about medication, making patients aware of the importance of compliance, reducing stigma, reassuring patients about side-effects and stressing the importance of carrying out general practitioners' advice. Measurements will take place at baseline, and after 3 and 6 months. Main outcome measure is compliance with antidepressants. Secondary outcomes include; clinical severity of depression (PHQ-9), anxiety (STAI-S), health-related quality of life (EuroQol-5D), satisfaction with the treatment received, side-effects, chronic physical conditions and sociodemographics. The use of healthcare and social care services will be assessed with an adapted version of the Client Service Receipt Inventory (CSRI). Discussion: This trial will provide valuable information for health professionals and policy makers on the effectiveness and cost-effectiveness of a pharmaceutical intervention programme in the context of primary care. Trial registration: NCT00794196

Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol.

Background: Treatment of depression, the most prevalent and costly mental disorder, needs to be improved. Non-concordance with clinical guidelines and non-adherence can limit the efficacy of pharmacological treatment of depression. Through pharmaceutical care, pharmacists can improve patients' compliance and wellbeing. The aim of this study is to evaluate the effectiveness and costeffectiveness of a community pharmacist intervention developed to improve adherence and outcomes of primary care patients with depression. Methods/design: A randomized controlled trial, with 6-month follow-up, comparing patients receiving a pharmaceutical care support programme in primary care with patients receiving usual care. The total sample comprises 194 patients (aged between 18 and 75) diagnosed with depressive disorder in a primary care health centre in the province of Barcelona (Spain). Subjects will be asked for written informed consent in order to participate in the study. Diagnosis will be confirmed using the SCID-I. The intervention consists of an educational programme focused on improving knowledge about medication, making patients aware of the importance of compliance, reducing stigma, reassuring patients about side-effects and stressing the importance of carrying out general practitioners' advice. Measurements will take place at baseline, and after 3 and 6 months. Main outcome measure is compliance with antidepressants. Secondary outcomes include; clinical severity of depression (PHQ-9), anxiety (STAI-S), health-related quality of life (EuroQol-5D), satisfaction with the treatment received, side-effects, chronic physical conditions and sociodemographics. The use of healthcare and social care services will be assessed with an adapted version of the Client Service Receipt Inventory (CSRI). Discussion: This trial will provide valuable information for health professionals and policy makers on the effectiveness and cost-effectiveness of a pharmaceutical intervention programme in the context of primary care. Trial registration: NCT00794196

Características de la Salud de las Personas Mayores que practican Ejercicio Físico de carácter comunitario en Catalunya con respecto otro tipo de prácticas dirigidas a este colectivo

Fundamentos. La Calidad de Vida Relacionada con la Salud (CVRS) es una forma de medir la salud aplicable en decisiones sanitarias o econòmicas. Se analizan los participantes en Programas de Ejercicio Físico Comunitario para Personas Mayores (PEFCPM) y se comparan con los de programas de Estimulación para Frágiles (EF), Caminatas, Petanca y Actividades Acuáticas (AA). Métodos. Se utiliza un muestreo intencional, de 2.268 usuarios de 60 o más años (media: 70,78 y DS: 6,16), realizado entre 2004 y 2008. Se analiza la CVRS, el Stock Capital Salud (SCS) y la medicación consumida (CM). La CVRS se obtiene mediante la Escala de Valoración Analógica (EVA) y el Sistema Descriptivo (SD) de 5 dimensiones del EuroQol. Para el SCS se multiplican las preferencias derivadas de las puntuaciones del SD por la Esperanza de Vida (EV) y por 34.858,70 €. El CM se calcula adaptando la Encuesta de Salud de Cataluña. Valores de la CVRS relacionados con la EVA, CM y SCS, se han analizado con metodología paramétrica. Para las dimensiones del SD, se han comparado los porcentajes de problemas. Resultados. Los usuarios de los PEFCPM obtienen una CVRS global de 70,74, un CM de 3,38 unidades y un SCS de 505.357,36 €/AVAC, que son resultados relativamente bajos respecto el resto de subgrupos. Conclusiones. Se obtienen perfiles de usuarios diferenciados según las características de su salud, lo que debemos tener en cuenta para promocionar el ejercicio físico. Aunque los hombres reflejan una valoración superior de su salud, su SCS es inferior a las mujeres practicantes. Esta tendencia es inversa a la de hombres y mujeres sedentarios.

Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: a randomized controlled superiority trial

Major depression is associated with high burden, disability and costs. Non-adherence limits the effectiveness of antidepressants. Community pharmacists (CP) are in a privileged position to help patients cope with antidepressant treatment. The aim of the study was to evaluate the impact of a CP intervention on primary care patients who had initiated antidepressant treatment. Newly diagnosed primary care patients were randomised to usual care (UC) (92) or pharmacist intervention (87). Patients were followed up at 6 months and evaluated three times (Baseline, and at 3 and 6 months). Outcome measurements included clinical severity of depression (PHQ-9), health-related quality of life (HRQOL) (Euroqol-5D) and satisfaction with pharmacy care. Adherence was continuously registered from the computerised pharmacy records. Non-adherence was defined as refilling less than 80% of doses or having a medication-free gap of more than 1 month. Patients in the intervention group were more likely to remain adherent at 3 and 6 months follow-up but the difference was not statistically significant. Patients in the intervention group showed greater statistically significant improvement in HRQOL compared with UC patients both in the main analysis and PP analyses. No statistically significant differences were observed in clinical symptoms or satisfaction with the pharmacy service. The results of our study indicate that a brief intervention in community pharmacies does not improve depressed patients' adherence or clinical symptoms. This intervention helped patients to improve their HRQOL, which is an overall measure of patient status.